慢性骨髄性白血病治療市場：薬剤タイプ別、投与経路別、流通チャネル別、地域別

世界の慢性骨髄性白血病治療市場は、2025年には90億4,000万米ドルと推定され、2032年には142億4,000万米ドルに達すると予測され、2025年から2032年にかけてCAGR6.7%で成長すると予測されています。

図.慢性骨髄性白血病治療市場シェア（%）、2025年地域別

慢性骨髄性白血病（CML）は骨髄で発症し、白血球の過剰産生につながるがんの一種です。CMLの主な原因は、骨髄における骨髄細胞の無制限な増殖と血液中への蓄積をもたらす遺伝子異常です。未治療のまま放置すると、CMLは慢性期から加速期、そして最終的には芽球クリーゼへと進行します。世界の慢性骨髄性白血病治療市場は、チロシンキナーゼ阻害剤のような革新的な標的治療薬のイントロダクションより、CML患者の臨床転帰とQOLが改善したため、近年著しい成長を遂げています。

市場力学：

世界の慢性骨髄性白血病治療市場は、CMLの世界の有病率の増加と早期診断・治療に対する意識の高まりによって牽引されています。さらに、従来の化学療法に比べて有効性と安全性に優れた新規の標的治療薬の開発・承認が市場の成長を後押ししています。しかし、特に価格に敏感な新興国市場では、標的治療薬の高価格が依然として主な課題となっています。プラス面では、ヘルスケア支出の増加と高級薬剤への需要が、市場プレーヤーに有利な機会を提供しています。さらに、新規治療アプローチを評価する臨床試験のための共同研究は、予測期間中に市場範囲をさらに拡大すると思われます。

本調査の主な特徴

本レポートでは、世界の慢性骨髄性白血病治療市場を詳細に分析し、2024年を基準年とした予測期間（2025-2032年）の市場規模およびCAGRを示します。

また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。

また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する主要考察も提供しています。

世界の慢性骨髄性白血病治療市場における主要企業を、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいてプロファイルしています。

本調査の対象となる主要企業には、Teva Pharmaceutical Industries Ltd.、F. Hoffmann-La Roche Ltd.、Novartis AG、Sanofi、Bristol-Myers Squibb Company、Pfizer Inc.、武田薬品工業株式会社、Innovent Biologics, Inc.、Viatris Inc.、Lupin、Million Health Pharmaceuticals、Celon Labs、Fresenius Kabi AGなどがあります。

本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品上市、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。

世界の慢性骨髄性白血病治療市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。

利害関係者は、世界の慢性骨髄性白血病治療市場の分析に使用される様々な戦略マトリックスを通じて意思決定を容易にすることができます。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー

第3章 市場力学、規制、動向の分析

• 市場力学
• 影響分析
• 主なハイライト
• 規制シナリオ
• 製品の発売/承認
• PEST分析
• PORTERの分析
• 合併と買収のシナリオ
• 疫学

第4章 慢性骨髄性白血病治療市場、薬剤タイプ別、2020年～2032年、（10億米ドル）

• チロシンキナーゼ阻害剤
• イマチニブ（グリバック）
• ダサチニブ（スプリセル）
• ニロチニブ（タシグナ）
• ボスチニブ（ボスリフ）
• ポナチニブ（イクルシグ）
• アシミニブ（センブリックス）
• その他
• 代謝拮抗物質
• その他

第5章 慢性骨髄性白血病治療市場、投与経路別、2020年-2032年、（10億米ドル）

• 経口
• 非経口
• 外用
• その他（鼻腔等）

第6章 慢性骨髄性白血病治療市場、流通チャネル別、2020年～2032年、（10億米ドル）

• 病院薬局
• 小売薬局
• オンライン薬局

第7章 慢性骨髄性白血病治療の世界市場、地域別、2020年～2032年、金額（10億米ドル）

• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第8章 競合情勢

• Teva Pharmaceutical Industries Ltd
• Hoffmann-La Roche Ltd.
• Novartis AG
• Sanofi
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Innovent Biologics, Inc.
• Viatris Inc.
• Lupin
• Million Health Pharmaceuticals
• Celon Labs
• Fresenius Kabi AG

第9章 アナリストの推奨事項

• 機会
• アナリストの見解
• Coherent Opportunity Map

第10章 参考文献と調査手法

• 参考文献
• 調査手法
• 出版社について

Global Chronic Myeloid Leukemia Treatment Market is estimated to be valued at USD 9.04 Bn in 2025 and is expected to reach USD 14.24 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.7% from 2025 to 2032.

Figure. Chronic Myeloid Leukemia Treatment Market Share (%), By Region 2025

Chronic myeloid leukemia (CML) is a type of cancer that starts in the bone marrow and leads to an overproduction of white blood cells. The main driver of CML is a genetic abnormality that leads to unrestrained growth of myeloid cells in the bone marrow and their accumulation in the blood. If left untreated, CML progresses from a chronic phase to an accelerated phase and finally to a blast crisis. The global chronic myeloid leukemia treatment market has witnessed significant growth in recent times owing to the introduction of innovative targeted therapies such as tyrosine kinase inhibitors that have improved the clinical outcome and quality of life of CML patients.

Market Dynamics:

The global chronic myeloid leukemia treatment market is driven by the increasing prevalence of CML worldwide and growing awareness about early diagnosis and treatment. Moreover, the development and approval of novel targeted drugs with better efficacy and safety profiles compared to conventional chemotherapy have boosted the market growth. However, the high cost of targeted therapies remains a key challenge, especially in price-sensitive developing markets. On the positive side, increasing healthcare expenditure and demand for premium drugs provide lucrative opportunities for market players. Additionally, collaborations for clinical trials evaluating novel treatment approaches will further expand the market reach during the forecast period.

Key features of the study:

This report provides in-depth analysis of the global chronic myeloid leukemia treatment market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global chronic myeloid leukemia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi, Bristol-Myers Squibb Company, Pfizer Inc., Takeda Pharmaceutical Company Limited, Innovent Biologics, Inc., Viatris Inc., Lupin, Million Health Pharmaceuticals, Celon Labs, and Fresenius Kabi AG

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global chronic myeloid leukemia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic myeloid leukemia treatment market

Detailed Segmentation-

• Drug Type Insights
  • Tyrosine Kinase Inhibitors
  • Imatinib (Gleevac)
  • Dasatinib (Sprycel)
  • Nilotinib (Tasigna)
  • Bosutinib (Bosulif)
  • Ponatinib (Iclusig)
  • Asciminib (Scemblix)
  • Others
  • Antimetabolites
  • Others
• Route of Administration Insights
  • Oral
  • Parenteral
  • Topical
  • Others (Nasal, etc.)
• Distribution Channel Insights
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Company Profiles:
  • Teva Pharmaceutical Industries Ltd
  • Hoffmann-La Roche Ltd.
  • Novartis AG
  • Sanofi
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Innovent Biologics, Inc.
  • Viatris Inc.
  • Lupin
  • Million Health Pharmaceuticals
  • Celon Labs
  • Fresenius Kabi AG

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Chronic Myeloid Leukemia Treatment Market, By Drug Type
  • Chronic Myeloid Leukemia Treatment Market, By Route of Administration
  • Chronic Myeloid Leukemia Treatment Market, By Distribution Channel
  • Chronic Myeloid Leukemia Treatment Market, By Region

3. Market Dynamics, Regulations, And Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Epidemiology

4. Chronic Myeloid Leukemia Treatment Market, By Drug Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Tyrosine Kinase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Imatinib (Gleevac)
• Dasatinib (Sprycel)
• Nilotinib (Tasigna)
• Bosutinib (Bosulif)
• Ponatinib (Iclusig)
• Asciminib (Scemblix)
• Others
• Antimetabolites
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Chronic Myeloid Leukemia Treatment Market, By Route of Administration, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Topical
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others (Nasal, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Chronic Myeloid Leukemia Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Chronic Myeloid Leukemia Treatment Market, By Region, 2020-2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug Type , 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel , 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Teva Pharmaceutical Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Hoffmann-La Roche Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Company Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Innovent Biologics, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Viatris Inc.
• Lupin
• Million Health Pharmaceuticals
• Celon Labs
• Fresenius Kabi AG

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us